The fibroblast growth factor 23 (FGF23) and Klotho system play a very important role in the regulation of the human body metabolism. On the one hand, they promote longevity, and on the other hand they promote insulin resistance. Nowadays, accelerated aging in diabetes as the main consequence of chronic complications of the disease is postulated. Signalling pathways induced by insulin, insulin-like growth factor (IGF-1), and their homologues play an important role in controlling the aging process. Because FGF23/Klotho system affects glucose metabolism and gene expression of antioxidant enzymes, changes in its concentration may be a marker of chronic complications of diabetes or a treatment option. Despite huge improvements in the treatment of diabetes, its chronic complications remain an important clinical problem. An interesting issue is the relationship between the concentration of FGF23/Klotho and management of the disease, duration, insulin resistance, and development of complications in type 1 diabetes. (Endokrynol Pol 2018; 69 (6): 696-704)
Introduction
Diabetes mellitus type 1 (DM1) is a chronic, autoimmune disease [1] . The number of people with DM1 is still increasing in every part of the world [2] . Patients with DM1 have worse quality of life in comparison to healthy counterparts [3] . Late diagnosis and uncontrolled disease leads to the development of long-term complications that cause disability, inability to work, and increased premature mortality [4] [5] [6] . Among the traditional risk factors of chronic complications, a crucial role is played by hyperglycaemia [7] and insulin resistance [8] , which includes decreased muscle, fat, and liver sensitivity to insulin [9] . Additional risk factors are dyslipidaemia [10] , arterial hypertension [11] , cigarette smoking [12] , and inflammation [7] . The Diabetes Control and Complications Trial (DCCT) [1] showed that in patients with DM1 appropriate metabolic control, provided by intensive insulin therapy, is fundamental in prevention and management of angiopathy. Long-term normalisation of blood glucose level can significantly decrease the risk of occurrence and delay progression of diabetes complications [13, 14] . However, despite improvements in the diagnosis and treatment of DM1, chronic complications remain a relevant, clinical problem. Retinopathy is the main reason for blindness, diabetic kidney disease is a leading cause of end-stage kidney failure, and neuropathy is responsible for non-injury amputations [15] . Thus, we are still looking for new, non-traditional risk factors of diabetic angiopathy among DM1 patients [16] .
The pathogenesis of chronic complications that occur among DM1 patients is very complicated. The most important factor is endothelial dysfunction causing microangiopathy, macroangiopathy, and neurodegeneration [17] . DM1 patients with associated microvascular complications have higher risk of accelerated atherosclerosis, which ultimately ends in cerebrovascular and cardiovascular events and premature death [18] . Small-vessel impairment is caused in the mechanism of oxidative stress and endothelial dysfunction [13, 19] . Hyperglycaemia and insulin resistance are the two major consequences of diabetes responsible for cardiovascular disorders [20] . They cause excessive reactive oxygen species (ROS) production, which at too high a level for a prolonged time or at an inappropriate subcellular location leads to impaired cellular function and cardiovascular pathology [20] . ROS activates nuclear poly (ADP ribose) polymerase (PARP), shunting early glycolytic intermediates into pathogenic signalling pathways. These changes cause decreased mitochondrial biogenesis and disturbed circadian clock synchronisation of glucose and lipid metabolism [20] . Another important pathomechanism causing angiopathic complications is increased inflammatory process [7] . Overproduction of reactive oxygen species (ROS) as a result of altered glucose metabolism and formation of advanced glycation end-products (AGE) activate nuclear factor κB (NFκB) and other proinflammatory pathways. In combination with endothelial cell insulin resistance, these changes cause endothelial dysfunction manifesting itself by increased expression of (Figure 1 ). Another leptin is a less well-known regulatory factor. Recent research has reported about the relationship between abdominal obesity and increasing FGF23 concentration [30] . Leptin stimulates the synthesis of FGF23 in the bones. There is an association of elevated leptin and FGF23 concentration with dyslipidaemia and adipose tissue mass [31] . This may be a risk factor for the development of insulin resistance, metabolic syndrome, and cardiovascular deaths, particularly in patients with long-lasting type 1 diabetes mellitus and metabolic decompensation [32] . More and more data show that the family of fibroblast growth factors influence regulation and carbohydrate homeostasis [33] .
Klotho as FGF23 cofactor
Klotho protein is a cofactor of FGF23 and is a necessary protein to affect FGF23 on the receptor [34] . It is a circulating hormone involved in insulin signalling, inflammation, and vascular homeostasis through its protective effects on the endothelium and antioxidant actions [35] . Klotho expression occurs in various tissues. The main synthesis site is the distal coils in the kidney, choroid plexus of the brain ventricles, and parathyroid glands. It also occurs in the liver, pancreas, and white adipose tissue [36] . It has two forms: membrane and secretory. Klotho protein has β-glucuronidase activity, and its secretory form is an endocrine regulator of glycoprotein function on the surface of cells [37] . The Klotho/FGF23 system works in reverse relation to vitamin D and according to the literature plays a comparable role to the PTH -vitamin D axis [23] .
Function of the Klotho protein
Klotho is a very important protein with a broad spectrum of activity (Fig. 2) . It affects glucose metabolism [38] . It is involved in the suppression of the insulin/IGF-1 pathway and thus participates in the regulation of cell function and growth. Signalling pathways induced by insulin, insulin-like growth factor (IGF-1), and their homologues play an important role in controlling the aging of many organisms [22] . This protein disrupts insulin-mediated phosphorylation, consequently inhibiting the activation of further proteins of the enzymatic pathway. In vitro, it has been demonstrated that this protein may also inhibit the phosphorylation of receptors previously activated by insulin or IGF-1. The activity of the secreted Klotho protein is specific for insulin and IGF-1 receptors because it does not show a similar effect to platelet-derived growth factor (PDGF) receptors and epidermal growth factor (EGF) receptors, which have tyrosine kinase activity [39, 40] . The enzymatic activity of Klotho suggests that it may also modify N-glycans of insulin and IGF-1 receptors, thereby blocking their activity and/or reducing the number of these receptors on the surface of cells. It blocks insulin-stimulated glucose uptake and contributes to the development of insulin resistance and all of its consequences [39] . It is suggested that the co-operation of two mechanisms contributes to the extension of life: inhibition of IGF-1 signalling and increased resistance to the oxidative pathway [41] . Blocking signal transmission on the insulin-dependent or IGF-1-dependent pathway leads to inhibition of Akt kinase. Akt active kinase phosphorylates the FOXO transcription factor. Only the non-phosphorylated FOXO factor, which is located in cell nucleus, acts as a transcription factor. Proteins belonging to the FOXO
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family are responsible for cell differentiation, embryogenesis, neoplasia, and metabolism regulation [42] . An important function is the regulation of gene expression of antioxidant enzymes such as catalase or mitochondrial manganese superoxide dismutase (SOD2). These enzymes remove reactive oxygen species and contribute to the reduction of oxidative stress, which can be an important factor in the process of inhibiting the aging of organisms that have inhibited the insulin/IGF-1 pathway [39] . Klotho protein increases hyperplasia of adipose tissue, and mice without this gene are resistant to the development of obesity induced by a high-fat diet [43] . Studies on animal models have shown that mutations that inactivate the Klotho gene reduce survival time and cause many disorders that contribute to premature aging. These disorders include osteoporosis, hypogonadotropic hypogonadism, atherosclerosis, skin atrophy, and neurodegenerative changes. It was found that mice devoid of the FGF23 and Klotho gene also experienced thymus atrophy, decreased triglycerides and glucose levels, and increased cholesterol levels [36] . Studies on severe nodular calcification as a result of the missense mutation of the human Klotho gene indicate the essential function of the Klotho protein [44] . What is more, recent studies show a relationship between vascular expression of this protein with diabetes and coronary disease [45] . The FGF23/Klotho system, in addition to the regulation of electrolyte management, plays a very important role in regulating the metabolism of the human body. On the one hand it promotes longevity, and on the other hand it promotes insulin resistance.
Is there a relationship between Klotho protein and type 1 diabetes?
Diabetic kidney disease is one of the most serious complications in patients with DM1 and one of the main predictors of premature death [46] . Renal impairments cause changes in the concentration of the described proteins. Chronic kidney disease leads to increased levels of FGF23 with a concomitant decrease in Klotho protein.
In the 2-3 phase of chronic kidney disease, when the phosphate is still normal and the PTH concentration is normal or moderately elevated, the concentration of FGF23 increases [47, 48] . Klotho-negative mice and patients with end-stage renal disease have common features such as hyperphosphataemia, vascular calcification, or high FGF23 concentration [49] . Diabetes mellitus as a chronic disease causes some complications, including nephropathy. It is also suggested that plasma Klotho concentration, or more precisely the disappearance of a compensatory increase in serum concentration, may be an early marker for predicting deterioration of renal function among patients with type 2 diabetes [50, 51] . We also know that serum Klotho may have a protective effect against atherosclerosis and endothelial dysfunction in type 1 DM [52] . Guo et al. revealed that Klotho might exert its cardioprotective effects by protecting cells from inflammation and oxidative stress. Thus, this work demonstrated for the first time that the anti-aging protein Klotho might be a potential therapeutic agent to treat diabetic cardiomyopathy by inhibiting oxidative stress and inflammation [53] . Recently, endocrine fibroblast growth factors have become attractive targets in the treatment of metabolic diseases, and results highlight the relevant use of FGFs as potential biomarkers for the early diagnosis of metabolic diseases [54] . However, there are still few studies showing similar correlations among patients with type 1 diabetes. An interesting question is whether among people with type 1 diabetes, along with an increase in FGF23 concentration and, consequently, a decrease in Klotho concentration, the features of aging are revealed and intensified.
Summary
Nowadays, there are no data showing changes in FGF23 and Klotho concentrations in people with type 1 diabetes. The literature reports that protein concentrations from the fibroblast growth factor family are increased in first-degree relatives of DM2 patients with pre-diabetes and that there is a strong association between fibroblast growth factor 21 (FGF 21) and obesity and insulin sensitivity [55] . We know that Klotho levels among patients with type 1 diabetes mellitus might be affected by renal impairment, hyperglycaemia, and high insulin doses [56] . It is possible that the Klotho protein synthesised in the pancreas plays a completely different role from the known one. Recent studies have reported that the synthesis in pancreatic cells cause suppressing beta-cell apoptosis in patients with type 1 diabetes [57] , and the findings of the latest studies suggest that the 
